Abstract: A microscope image of a cultured cell cluster derived from a cancer specimen of a patient is acquired. A measured value of a gene expression level of the cluster is acquired. Based on the image, a morphological representation identifiably expressing, by a vector quantity of a plurality of dimensions, a morphological difference between a group of cell clusters cultured from the same cancer specimen and a group of cell clusters cultured from another cancer specimen is acquired. The acquired morphological representation is input to a function, which is obtained by fitting the measured value with respect to the morphological representation, to acquire a prediction value of the gene expression level. Prediction accuracy is estimated based on the prediction value and the measured value. Based on the estimated prediction accuracy, a gene related to a morphological change of the cell cluster is extracted as a gene candidate.

Abstract: Provided is, as a radioactive halogen labeling precursor compound that is highly reactive and stable, a compound represented by the following general formula (II): wherein R1 and R2 each independently represent an alkyl group having 5 to 20 carbon atoms, X1 and X2 each independently represent a halogen atom, and R3 represents a monovalent group derived from a sugar, or the like.

Abstract: In order to produce high yields of astatine-211 without contamination of chloride ions, provided is a method for producing astatine-211, including (1) a step of generating astatine-211 by irradiating bismuth with ? rays; (2) a step of heating the astatine-211 generated in step (1) to vaporize; (3) a step of cooling the astatine-211 that has been vaporized in step (2) and collecting the astatine-211 with a volatile and polar solvent to obtain an astatine-211 solution; (4) a step of adding a weak acid salt to the astatine-211 solution obtained in step (3) to obtain an astatine-211 solution containing the weak acid salt; and (5) a step of removing the solvent from the astatine-211 solution containing the weak acid salt obtained in step (4).

Abstract: It is an object of the present invention to provide a novel halogenated biotin-modified dimer capable of performing imaging diagnosis or treatment. According to the present invention, a compound represented by the following formula (1) or a salt thereof is provided: wherein L1 represents a trivalent linking group, L2 represents a divalent linking group, Hal represents a halogen, p represents an integer of 1 to 5, and q, r, s, and t each independently represent an integer of 1 to 8.

Abstract: In one embodiment, a problem to be addressed by the present invention is to provide a novel cellular immunotherapy having a treatment and/or prevention effect against a tumor. In one embodiment, the present invention relates to a composition for use in treatment and/or prevention of a tumor in a subject comprising allogeneic CD4+ T cells, wherein the allogeneic CD4+ T cells have (a) MHC class II molecules all or part of which are different from MHC class II molecules of the subject, and contain (b) cells activated by ex vivo coculture with antigen-presenting cells derived from the subject or an individual having MHC class II molecules wholly identical or partially identical with the MHC class II molecules of the subject.

Abstract: In one embodiment, the present invention provides a method for a plurality of cells comprising screening of a part of the cells without subculturing all of the cells and selecting a part of the cells based on the results. In one embodiment, the present invention relates to a method of producing a culture cell, comprising the steps of: a) culturing a plurality of animal cells or plant cells in a culture vessel by adherent culture or on a semisolid medium to form a plurality of colonies each of which is derived from a single cell; b) detecting a sequence of one or more base(s) in a nucleic acid for a part of said plurality of colonies by a nucleic acid or protein detection method, during which said plurality of colonies are cultured in a culture vessel; and c) selecting and collecting said part of the colonies based on the results of said detection method.

Abstract: An objective of the present invention is to provide a novel biomarker for predicting the prognosis of an endometrial cancer patient. A biomarker that comprises a claudin 6 protein or a peptide fragment thereof, or a transcription product of a claudin 6 gene or a nucleic acid fragment thereof is provided so as to predict the prognosis of an endometrial cancer patient.

Abstract: The present invention provides a component that promotes cell adhesion, cell proliferation, and maintenance of stem cell potential. The invention relates to a peptide containing DPRIEWKKI (SEQ ID NO: 33), or an amino acid sequence obtained by adding, deleting, and/or substituting one amino acid therein. The invention relates to a coating agent for a cell culture substrate, an agent for promoting cell proliferation, an agent for maintaining stem cell potential, or a culture medium containing the peptide or salt thereof. The invention further relates to a cell culture substrate coated with the peptide or salt thereof. The present invention also relates to a method of culturing a cell which uses the coating agent, the cell culture substrate, the agent for promoting cell proliferation, or the agent for maintaining stem cell potential and to a method of producing a cell culture substrate by coating a cell culture substrate with the coating agent.

Abstract: To provide a porous plate for medical use which can suppress bending along a row direction and, even if a local crack occurs, can inhibit the crack from growing and leading to a fracture. One aspect of the present invention is a porous plate for medical use which is a thin-plate substrate provided with a pore perforation section having a plurality of pores perforated therein and a frame section surrounding the pore perforation section. In this porous plate, the pore perforation section has crosspieces which extend lengthwise and crosswise in continuity with the frame section and partition the pore perforation section into a plurality of parts, and a plurality of pore perforation cells each surrounded by the crosspieces. The pores perforated in the pore perforation cells have a pore diameter calculated as an equivalent circular pore diameter of 1 to 50 ?m, and the center-to-center distance between the adjacent pores is 2 to 200 ?m.

Abstract: An inhibitor of HCV infection having a high inhibitory effect on HCV infection wherein the effect is unaffected by genotypes or gene mutations of HCV is developed and provided. The present invention provides an anti-occludin antibody binding to a peptide which consists of a portion of an amino acid sequence constituting a second extracellular domain of occludin and contains the amino acid sequence represented by SEQ ID NO: 1 as an epitope.

Abstract: To provide a porous plate for medical use which can suppress bending along a row direction and, even if a local crack occurs, can inhibit the crack from growing and leading to a fracture. One aspect of the present invention is a porous plate for medical use which is a thin-plate substrate provided with a pore perforation section having a plurality of pores perforated therein and a frame section surrounding the pore perforation section. In this porous plate, the pore perforation section has crosspieces which extend lengthwise and crosswise in continuity with the frame section and partition the pore perforation section into a plurality of parts, and a plurality of pore perforation cells each surrounded by the crosspieces. The pores perforated in the pore perforation cells have a pore diameter calculated as an equivalent circular pore diameter of 1 to 50 ?m, and the center-to-center distance between the adjacent pores is 2 to 200 ?m.